Abbott Laboratories Stock Total Debt
| ABL Stock | EUR 108.06 0.44 0.41% |
Abbott Laboratories fundamentals help investors to digest information that contributes to Abbott Laboratories' financial success or failures. It also enables traders to predict the movement of Abbott Stock. The fundamental analysis module provides a way to measure Abbott Laboratories' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Abbott Laboratories stock.
Abbott |
Abbott Laboratories Company Total Debt Analysis
Abbott Laboratories' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Abbott Laboratories Total Debt | 14.52 B |
Most of Abbott Laboratories' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Abbott Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Abbott Laboratories has a Total Debt of 14.52 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Medical Devices industry. The total debt for all Germany stocks is 173.11% lower than that of the firm.
Abbott Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Abbott Laboratories' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Abbott Laboratories could also be used in its relative valuation, which is a method of valuing Abbott Laboratories by comparing valuation metrics of similar companies.Abbott Laboratories is currently under evaluation in total debt category among its peers.
Abbott Fundamentals
| Return On Equity | 0.19 | |||
| Return On Asset | 0.0738 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 190.22 B | |||
| Shares Outstanding | 1.74 B | |||
| Shares Owned By Insiders | 0.70 % | |||
| Shares Owned By Institutions | 76.37 % | |||
| Price To Earning | 41.25 X | |||
| Price To Book | 5.40 X | |||
| Price To Sales | 3.91 X | |||
| Revenue | 43.65 B | |||
| Gross Profit | 24.58 B | |||
| EBITDA | 12.13 B | |||
| Net Income | 6.93 B | |||
| Cash And Equivalents | 8.37 B | |||
| Cash Per Share | 4.71 X | |||
| Total Debt | 14.52 B | |||
| Debt To Equity | 0.55 % | |||
| Current Ratio | 1.75 X | |||
| Book Value Per Share | 21.11 X | |||
| Cash Flow From Operations | 9.58 B | |||
| Earnings Per Share | 3.69 X | |||
| Price To Earnings To Growth | 18.63 X | |||
| Target Price | 132.05 | |||
| Number Of Employees | 115 K | |||
| Beta | 0.65 | |||
| Market Capitalization | 167.05 B | |||
| Total Asset | 74.44 B | |||
| Z Score | 6.6 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 1.70 % | |||
| Net Asset | 74.44 B | |||
| Last Dividend Paid | 1.92 |
About Abbott Laboratories Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Abbott Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abbott Laboratories using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abbott Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Abbott Stock
When determining whether Abbott Laboratories is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Abbott Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Abbott Laboratories Stock. Highlighted below are key reports to facilitate an investment decision about Abbott Laboratories Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Abbott Stock please use our How to Invest in Abbott Laboratories guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.